Table of contents
- Overview of the Ulonivirine studies
- Who is being studied
- Study designs and phases
- What the trials measure
- Main trial details
- Key points for patients
Overview of the Ulonivirine studies
The available clinical trials are studying Ulonivirine in people with HIV-1 infection or HIV.[1][2] These studies are focused on whether the treatment plan is safe, well tolerated, and able to lower the amount of virus in the blood.[1][2]
One trial is completed and one is authorised, so the research includes both finished and ongoing study planning.[1][2]
Who is being studied
The studies include people with HIV-1 infection, and one trial specifically focuses on people with HIV-1 who have not been treated before.[1][2] This means the research is looking at both treatment-naive participants, which means people who have not yet received treatment, and other HIV populations in a switch setting.[1]
The authorised study enrolls a larger group, with 520 participants, while the completed Phase 2 trial enrolled 161 participants.[1][2]
Study designs and phases
Both studies are interventional trials, which means researchers assign the study treatments rather than only observing what happens in routine care.[1][2] The completed study is a Phase 2 dose-ranging and switch study, while the authorised study is described as Phase 4.[1][2]
The Phase 2 trial studied once-weekly treatment strategies, including Ulonivirine as part of the study plan.[1] The authorised study compares once-weekly islatravir and Ulonivirine with a standard daily treatment regimen in people with HIV-1 who have not been treated before.[2]
What the trials measure
The main outcomes in these trials focus on safety, tolerability, and antiretroviral activity, which means how well the treatment controls HIV.[1][2]
- Adverse events: the studies count how many participants have at least one adverse event, which is any health problem that happens during the trial.[1][2]
- Stopping study treatment because of an adverse event: the trials measure how many participants stop the study intervention due to a health problem.[1][2]
- HIV-1 RNA below 50 copies/mL: this is a key effectiveness measure showing how many participants reach a low level of virus in the blood.[2]
In the authorised study, these outcomes are measured at Week 24 for Phase 2 and at Week 48 for Phase 3.[2]
Main trial details
NCT04564547 is a completed Phase 2 study in 161 participants with HIV-1 infection.[1] It was designed as a dose-ranging and switch study and mainly evaluated the safety and tolerability of once-weekly treatment strategies, including Ulonivirine.[1]
2025-522519-40-00 is an authorised Phase 4 study with 520 participants and focuses on people with HIV who have not been treated before.[2] It compares once-weekly islatravir and Ulonivirine with a standard daily regimen, and it measures both virus control and safety over time.[2]
| Trial ID | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04564547 | Dose Ranging, Switch Study of ISL and MK‑8507 Once-Weekly | Phase 2 | Completed | 161 |
| 2025-522519-40-00 | A clinical study of islatravir and ulonivirine for people with HIV-1 who have not been treated before (MK-8591B-062) | Phase 4 | Authorised | 520 |
Key points for patients
These trials do not describe Ulonivirine as a stand-alone treatment; instead, they study it as part of HIV treatment combinations.[1][2] The main questions are whether the treatment plan works, whether it is safe, and whether people can stay on it without major problems.[1][2]
Because the studies include different phases and different participant groups, they help researchers learn about Ulonivirine in both earlier and later stages of clinical research.[1][2]
